AP NEWS

Fabry Disease - Pipeline Insight, 2019 - ResearchAndMarkets.com

January 24, 2019

DUBLIN--(BUSINESS WIRE)--Jan 24, 2019--The “Fabry Disease - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Fabry Disease - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Fabry Disease pipeline products by developmental stage, product type, molecule type, and administration route.

Companies Featured

Actelion Ltd. Amicus Therapeutics Inc. Genzyme Corp. Greenovation Biotech GmbH JCR Pharmaceuticals Co. Ltd. Neuraltus Pharmaceuticals Inc. Pharming Group N.V. Protalix BioTherapeutics Inc. Sangamo Therapeutics Inc. Shire PLC

Topics Covered

1. Report Introduction

2. Fabry Disease Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Fabry Disease

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

Product Description Research and Development Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/g4pl4h/fabry_disease?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190124005695/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/24/2019 01:25 PM/DISC: 01/24/2019 01:25 PM

http://www.businesswire.com/news/home/20190124005695/en

AP RADIO
Update hourly